MAPK1 and metabolic dysfunction-associated steatotic liver disease: It could exhibit the hepatoprotective effect on NAFLD by improving the levels of ALT, AST, TC,TG, HDL-C, LDL-C, decreasing protein expressions of IL-6, MAPK1, Caspase 3, p53, VEGFA, and increasing protein expression of AKT1.